53 citations
,
August 2005 in “The Journal of Cell Biology” Sgk3 is essential for normal hair follicle growth and maintenance.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
Baricitinib shows promise for treating alopecia areata with mild side effects.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
15 citations
,
November 2024 in “Journal of Advanced Research” miR-3606-3p reduces skin fibrosis by blocking key signaling pathways.
ERK activation spreads between cells in mouse skin, linked to cell division and influenced by TPA and EGF receptors.
2 citations
,
November 2024 in “In Silico Pharmacology” 56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
1 citations
,
February 2013 in “InTech eBooks” LEKTI is crucial for skin barrier and immune function, affecting conditions like Netherton syndrome and atopic dermatitis.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
January 2026 in “Biomolecules” TSC22D genes are key in metabolic diseases and cancer, offering potential as treatment targets.
2 citations
,
July 2025 in “Acta Pharmacologica Sinica” Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
24 citations
,
December 2013 in “Archives of Dermatological Research” August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
January 2022 in “Social Science Research Network” Pyruvate Kinase M2 helps hair grow by linking energy production and a key hair growth pathway.
April 2026 in “International Journal of Clinical Oncology” The review by the Japanese Pharmacist-led Oncodermatology Study Team highlights that combining immune checkpoint inhibitors (ICIs) with chemotherapy or molecularly targeted therapy can exacerbate skin toxicities in Asian patients. Analyzing 28 studies out of 7,287 articles, the review focuses on capecitabine-induced hand-foot syndrome (HFS), multikinase inhibitor-induced hand-foot skin reaction (HFSR), taxane-induced alopecia, and EGFR inhibitor-related skin toxicities. The addition of ICIs was associated with a higher incidence of these skin toxicities, particularly capecitabine-related HFS and EGFR inhibitor-related skin issues. The findings emphasize the need for careful monitoring and management strategies to address these dermatologic side effects in combination therapies, as ICIs, while improving cancer survival rates, can amplify drug-specific skin toxicities through shared inflammatory pathways and immune cell recruitment to the skin. The study suggests that ICIs may enhance immune activity, potentially exacerbating skin toxicities, and highlights the need for preventive strategies and tailored treatment approaches for Asian populations.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.
23 citations
,
November 2015 in “Phytotherapy Research” Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.